Trial Profile

Clinical study of enzalutamide on castration resistant prostate cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enzalutamide (Primary)
Indications Prostate cancer
Focus Therapeutic Use

Most Recent Events

12 May 2023 Results investigating the relationship between the serum testosterone (T) level before ENZ treatment and QoL changes in CRPC patients, published in the Prostate
19 Feb 2022 Results investigating the relationship between serum testosterone (T) levels before ENZ and QOL changes in CRPC patients, presented at the 2022 Genitourinary Cancers Symposium
13 Sep 2021 Results of an analysis assessing the the relationship between the efficacy of Enzalutamide on castration resistant prostate cancer and serum androgen concentrations before administration presented at the 116th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com